The Medical Letter on Drugs and Therapeutics
Telaprevir (Incivek) and Boceprevir (Victrelis) for Chronic Hepatitis C
The full article is available to subscribers Subscriber Login   
Revised 10/26/11: In the clinical studies section for telaprevir, "among patients who had a previous relapse" was added to the REALIZE trial sentence.

Telaprevir (Incivek – Vertex) and boceprevir (Victrelis – Merck) have been approved by the FDA for oral use in combination with peginterferon and ribavirin for treatment of chronic hepatitis C virus (HCV) genotype 1 infection in adults with compensated liver disease. Both telaprevir and boceprevir were developed specifically to inhibit the NS3/4A proteases that cleave HCV encoded polyproteins of the genotype 1 virus.

STANDARD THERAPY — Peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) plus oral ribavirin (Rebetol, Copegus, and others) have been the drugs of choice for treatment of chronic HCV infection.1 They produce sustained virologic responses (SVRs) – undetectable plasma HCV RNA 24 weeks after cessation of therapy – in 40-50% of patients with genotype 1 HCV infection. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Telaprevir (Incivek) and Boceprevir (Victrelis) for Chronic Hepatitis C
Article code: 1369a
 Electronic, downloadable article - $25